NYSE:GMED Globus Medical (GMED) Stock Price, News & Analysis → The World’s Richest Man Blindsided by AI (From Banyan Hill Publishing) (Ad) Free GMED Stock Alerts $62.55 -1.20 (-1.88%) (As of 12:52 PM ET) Add Compare Share Share Today's Range$62.13▼$64.5450-Day Range$49.79▼$64.7252-Week Range$43.38▼$65.74Volume255,691 shsAverage Volume1.18 million shsMarket Capitalization$8.47 billionP/E Ratio97.74Dividend YieldN/APrice Target$66.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Globus Medical alerts: Email Address Globus Medical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.55 Rating ScoreUpside/Downside6.2% Upside$66.50 Price TargetShort InterestBearish6.64% of Shares Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.65Based on 61 Articles This WeekInsider TradingSelling Shares$1.85 M Sold Last QuarterProj. Earnings Growth17.08%From $2.81 to $3.29 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.44 out of 5 starsMedical Sector339th out of 2,771 stocksSurgical & Medical Instruments Industry49th out of 300 stocks 2.3 Analyst's Opinion Consensus RatingGlobus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 6 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageGlobus Medical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Globus Medical's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.64% of the outstanding shares of Globus Medical have been sold short.Short Interest Ratio / Days to CoverGlobus Medical has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Globus Medical has recently increased by 19.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlobus Medical does not currently pay a dividend.Dividend GrowthGlobus Medical does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlobus Medical has received a 57.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Synthetic bone grafts", "Artificial joints", and "Robotic surgery systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Globus Medical is -0.93. Previous Next 2.6 News and Social Media Coverage News SentimentGlobus Medical has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 61 news articles for Globus Medical this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for GMED on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows6 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,850,574.00 in company stock.Percentage Held by Insiders24.30% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Globus Medical's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Globus Medical are expected to grow by 17.08% in the coming year, from $2.81 to $3.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Globus Medical is 97.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.44.Price to Earnings Ratio vs. SectorThe P/E ratio of Globus Medical is 97.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 132.08.Price to Earnings Growth RatioGlobus Medical has a PEG Ratio of 1.81. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGlobus Medical has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Globus Medical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceCrypto Pioneer Says: “The last crypto bull market has begun.”Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos… About Globus Medical Stock (NYSE:GMED)Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Read More GMED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMED Stock News HeadlinesMay 11 at 9:21 AM | insidertrades.comGlobus Medical, Inc. (NYSE:GMED) Director Sells $1,300,000.00 in StockMay 13 at 3:14 AM | markets.businessinsider.comTruist Financial Keeps Their Hold Rating on Globus Medical (GMED)May 12 at 5:06 AM | americanbankingnews.comDavid D. Davidar Sells 20,000 Shares of Globus Medical, Inc. (NYSE:GMED) StockMay 12 at 3:51 AM | americanbankingnews.comRoth Capital Research Analysts Cut Earnings Estimates for Globus Medical, Inc. (NYSE:GMED)May 11 at 5:31 AM | americanbankingnews.comPiper Sandler Raises Globus Medical (NYSE:GMED) Price Target to $60.00May 11 at 5:31 AM | americanbankingnews.comGlobus Medical (NYSE:GMED) Price Target Raised to $70.00May 10, 2024 | americanbankingnews.comGlobus Medical (NYSE:GMED) PT Raised to $63.00 at BTIG ResearchMay 10, 2024 | americanbankingnews.comGlobus Medical, Inc. (NYSE:GMED) Expected to Post FY2026 Earnings of $3.77 Per ShareMay 10, 2024 | americanbankingnews.comGlobus Medical (NYSE:GMED) Stock Rating Reaffirmed by Needham & Company LLCMay 10, 2024 | americanbankingnews.comAnalysts Issue Forecasts for Globus Medical, Inc.'s Q2 2024 Earnings (NYSE:GMED)May 10, 2024 | msn.comGlobus Medical Reports Strong Sales Growth Post-NuVasive Merger Despite Quarterly Net LossMay 9, 2024 | msn.comGlobal Partners LP (NYSE:GLP) Q1 2024 Earnings Call TranscriptMay 9, 2024 | benzinga.comKey Takeaways From Globus Medical Analyst RatingsMay 9, 2024 | americanbankingnews.comFY2025 EPS Estimates for Globus Medical, Inc. Increased by Zacks Research (NYSE:GMED)May 9, 2024 | finance.yahoo.comThree Growth Companies With High Insider Ownership And 36% Earnings GrowthMay 9, 2024 | americanbankingnews.comGlobus Medical (NYSE:GMED) Hits New 1-Year High on Better-Than-Expected EarningsMay 8, 2024 | marketwatch.comGlobus Medical Shares Rise 22% on Raised FY Outlook, 1Q Revenue BeatMay 8, 2024 | markets.businessinsider.comStrong Buy: Globus Medical’s Robust Performance and Strategic Growth OutlookMay 8, 2024 | markets.businessinsider.comGlobus Medical Up 23% As Q1 Results Beat Street; Raises FY OutlookMay 8, 2024 | msn.comGlobus Medical Shares Race Higher After Better-Than-Expected Q1 ResultsMay 8, 2024 | finance.yahoo.comGlobus Medical, Inc. (NYSE:GMED) Q1 2024 Earnings Call TranscriptMay 8, 2024 | msn.comGMED Stock Earnings: Globus Medical Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | fool.comGlobus Medical (GMED) Q1 2024 Earnings Call TranscriptMay 7, 2024 | msn.comGlobus Medical up 11% on guidance boost, Q1 resultsMay 7, 2024 | globenewswire.comGlobus Medical Reports First Quarter 2024 ResultsSee More Headlines Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/14/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNYSE:GMED CUSIP37957720 CIK1237831 Webwww.globusmedical.com Phone(610) 930-1800Fax610-930-2042Employees5,000Year FoundedN/APrice Target and Rating Average Stock Price Target$66.50 High Stock Price Target$85.00 Low Stock Price Target$53.00 Potential Upside/Downside+6.3%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$0.64 Trailing P/E Ratio97.78 Forward P/E Ratio22.27 P/E Growth1.81Net Income$122.87 million Net Margins3.51% Pretax Margin4.93% Return on Equity8.82% Return on Assets7.06% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio1.29 Sales & Book Value Annual Sales$1.57 billion Price / Sales5.40 Cash Flow$3.49 per share Price / Cash Flow17.94 Book Value$29.32 per share Price / Book2.13Miscellaneous Outstanding Shares135,370,000Free Float102,477,000Market Cap$8.47 billion OptionableOptionable Beta1.11 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. David C. Paul (Age 57)Co-Founder & Executive Chairman Comp: $1.09MMr. Daniel T. Scavilla (Age 59)President, CEO & Director Comp: $1.37MMr. Keith W. Pfeil (Age 44)CFO & COO Comp: $675.89kMs. Kelly G. Huller Esq. (Age 52)Senior VP, General Counsel & Secretary Comp: $543.24kMr. Brian J. Kearns (Age 57)Senior Vice President of Business Development & Investor Relations Key CompetitorsTeleflexNYSE:TFXIntegra LifeSciencesNASDAQ:IARTAlphatecNASDAQ:ATECInsuletNASDAQ:PODDBaxter InternationalNYSE:BAXView All CompetitorsInsiders & InstitutionsBurgundy Asset Management Ltd.Bought 782,285 shares on 5/14/2024Ownership: 1.832%American International Group Inc.Sold 3,131 shares on 5/14/2024Ownership: 0.113%CANADA LIFE ASSURANCE CoSold 14,171 shares on 5/14/2024Ownership: 0.048%NatixisSold 16,704 shares on 5/14/2024Ownership: 0.026%Bessemer Group Inc.Bought 7,294 shares on 5/13/2024Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions GMED Stock Analysis - Frequently Asked Questions Should I buy or sell Globus Medical stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GMED shares. View GMED analyst ratings or view top-rated stocks. What is Globus Medical's stock price target for 2024? 11 analysts have issued 12 month price objectives for Globus Medical's stock. Their GMED share price targets range from $53.00 to $85.00. On average, they predict the company's stock price to reach $66.50 in the next year. This suggests a possible upside of 6.2% from the stock's current price. View analysts price targets for GMED or view top-rated stocks among Wall Street analysts. How have GMED shares performed in 2024? Globus Medical's stock was trading at $53.29 on January 1st, 2024. Since then, GMED stock has increased by 17.5% and is now trading at $62.64. View the best growth stocks for 2024 here. Are investors shorting Globus Medical? Globus Medical saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 8,990,000 shares, an increase of 19.7% from the April 15th total of 7,510,000 shares. Based on an average daily volume of 1,120,000 shares, the days-to-cover ratio is currently 8.0 days. View Globus Medical's Short Interest. When is Globus Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our GMED earnings forecast. How were Globus Medical's earnings last quarter? Globus Medical, Inc. (NYSE:GMED) issued its quarterly earnings results on Tuesday, May, 7th. The medical device company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.55 by $0.17. The medical device company earned $606.67 million during the quarter, compared to analyst estimates of $586.82 million. Globus Medical had a net margin of 3.51% and a trailing twelve-month return on equity of 8.82%. Globus Medical's revenue for the quarter was up 119.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.53 earnings per share. What ETFs hold Globus Medical's stock? ETFs with the largest weight of Globus Medical (NYSE:GMED) stock in their portfolio include Motley Fool Mid-Cap Growth ETF (TMFM), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Indxx Medical Devices ETF (MDEV), SPDR S&P Health Care Equipment ETF (XHE), iShares U.S. Medical Devices ETF (IHI) and SPDR S&P 400 Mid Cap Value ETF (MDYV). What guidance has Globus Medical issued on next quarter's earnings? Globus Medical updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of 2.750-2.850 for the period, compared to the consensus earnings per share estimate of 2.690. The company issued revenue guidance of $2.5 billion-$2.5 billion, compared to the consensus revenue estimate of $2.5 billion. What is David Demski's approval rating as Globus Medical's CEO? 47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA). Who are Globus Medical's major shareholders? Globus Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.09%), Bank of New York Mellon Corp (2.23%), Champlain Investment Partners LLC (1.85%), Burgundy Asset Management Ltd. (1.83%), William Blair Investment Management LLC (1.65%) and Geneva Capital Management LLC (1.16%). Insiders that own company stock include Dan Lemaitre, Daniel T Scavilla, Daniel T Scavilla, David D Davidar, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Leslie V Norwalk. View institutional ownership trends. How do I buy shares of Globus Medical? Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:GMED) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
